TFEB and cancer: Recent work shows that lysosomotropic anti‐cancer drugs promote lysosome‐mediated cancer drug resistance by stimulating activation of TFEB and the consequent increase in lysosomal biogenesis, lysosomal exocytosis, and autophagy (Zhitomirsky et al, 2018).